Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) FCF Margin (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of FCF Margin data on record, last reported at 349.07% in Q4 2025.

  • For Q4 2025, FCF Margin fell 11800.0% year-over-year to 349.07%; the TTM value through Dec 2025 reached 396.64%, down 18510.0%, while the annual FY2025 figure was 396.64%, 18510.0% down from the prior year.
  • FCF Margin reached 349.07% in Q4 2025 per OCUL's latest filing, up from 389.98% in the prior quarter.
  • Across five years, FCF Margin topped out at 17.44% in Q3 2023 and bottomed at 435.63% in Q1 2025.
  • Average FCF Margin over 5 years is 203.18%, with a median of 158.91% recorded in 2023.
  • Peak YoY movement for FCF Margin: skyrocketed 76004bps in 2021, then tumbled -26513bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 131.2% in 2021, then decreased by -3bps to 135.76% in 2022, then decreased by -10bps to 150.01% in 2023, then crashed by -54bps to 231.07% in 2024, then tumbled by -51bps to 349.07% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 349.07% in Q4 2025, 389.98% in Q3 2025, and 419.67% in Q2 2025.